Company Overview of aTyr Pharma Inc.
aTyr Pharma Inc., a protein therapeutics company, engages in the discovery and development of biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.
3565 General Atomics Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
President and Chief Operating Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Inc. Presents at Boston CEO Conference, Jun-04-2014
Jun 2 14
aTyr Pharma Inc. Presents at Boston CEO Conference, Jun-04-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Presentation Date & Speakers: Jun-04-2014, John D. Mendlein, Executive Chairman and Chief Executive Officer.
aTyr Pharma Completes First Phase 1 Study for Rare Disease Program
May 21 14
aTyr Pharma announced completion of Phase 1 for its lead program, Resokine IV, which marked the first ever administration of a Physiocrine to humans, was conducted in healthy male and female subjects in the European Union to assess the safety and tolerability of Resokine IV. aTyr Pharma is developing Resokine IV as a potential therapeutic for rare immune disorders. This study advances a range of therapeutic programs to treat rare immune-imbalanced diseases and develop a rare disease pipeline in immunology. The Phase 1 study was a double blinded, placebo-controlled, trial demonstrating that Resokine IV was well tolerated and safe at all doses tested. No serious adverse effects were observed. The data from 32 healthy subjects in four dose cohorts supports the basic premise of Resokine IV as an immuno-modulator rather than a classic interleukin or interferon with systemic immuno-stimulating properties upon administration.
aTyr Pharma Appoints Biotech Pioneer, Dr. Ed Penhoet, to Board of Directors
Mar 28 14
aTyr Pharma (aTyr) announced the appointment of Ed Penhoet, Ph.D., to the company's board of directors (BOD). Dr. Penhoet, who co-founded Chiron, is an accomplished scientist and biotech pioneer. He has served on the Independent Citizens Oversight Committee (ICOC) for the California Institute of Regenerative Medicine (CIRM) and was recently appointed to President Obama's Council of Advisors on Science and Technology (PCAST). On aTyr's BOD, Dr. Penhoet will represent Alta Partners, an aTyr investor.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 29, 2013